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ANNOUNCEMENT 
The 43rd Annual Symposium on the Biology of Skin will be held in Snowmass, Colorado 
August 6 - 10, 1994. The topic of this year's meeting will be "Lymphocytes in Skin Disease: 
From Activation to Immunodeficiency." 
The meeting will consist of invited oral and poster presentations. Enrollment is limited to 
150 participants. A limited number of posters will be accepted for presentation. Deadline for 
poster abstract submission is June 1, 1994. Those wishing to submit abstracts for poster presen-
tations or requesting registration materials should write to David A. Norris, M.D., The Cuta-
neous Biology Foundation, Box B-144, Department of Dermatology, University of Colorado 
School of Medicine, 4200 E. Ninth Avenue, Denver, CO 80262. 
